For healthcare professionals, the presence of falsified medicines in the supply chain can be detrimental to both patient safety and the reputation of their practice. In this article, we will explore the dangers of falsified medicines and how working with a WDA(H) holder like Burlington Pharma can mitigate these risks.

The Threat of Falsified Medicines: Risks to Healthcare Professionals and Patients

Falsified medicines are a growing global concern, with the World Health Organization (WHO) estimating that up to 1 in 10 medical products in low- and middle-income countries are either substandard or falsified. However, this problem is not limited to specific regions—globalization and complex supply chains mean falsified medicines can infiltrate even highly regulated markets.

1. Patient Safety

The most critical concern with falsified medicines is their impact on patient safety. These products may contain incorrect or harmful ingredients, be contaminated, or lack the active pharmaceutical ingredients (API) required to treat a patient’s condition effectively. For example, a falsified antibiotic might not contain enough of the active substance to eradicate an infection, leading to treatment failure or the development of antibiotic resistance.

The use of falsified medicines can result in:

• Adverse drug reactions (ADRs): Patients may experience unexpected side effects or allergic reactions due to the presence of undeclared or incorrect substances.
• Therapeutic failure: Substandard or diluted products may not treat the disease as intended, prolonging illness or worsening conditions.
• Death: In extreme cases, the use of falsified medicines can lead to fatal outcomes, especially in critical therapies like chemotherapy or anti-retroviral treatments.

2. Reputation of Healthcare Practices

For healthcare professionals, unknowingly administering falsified medicines can severely damage the reputation of their practice. Patients trust that healthcare providers deliver safe, reliable treatment. If a falsified medicine is detected or a patient suffers harm, it could lead to legal consequences, loss of patient trust, and even regulatory sanctions for the healthcare provider.

Furthermore, the use of falsified medicines can complicate diagnostic processes. If a patient’s condition does not improve or worsens despite treatment, healthcare professionals may misattribute this to misdiagnosis or incorrect treatment plans, leading to ineffective or delayed treatment.

3. Impact on Public Health

Beyond individual patient outcomes, falsified medicines can undermine public health efforts. The use of ineffective medicines in widespread conditions like malaria, tuberculosis, or HIV can lead to outbreaks, resistance, and the erosion of confidence in the healthcare system.

The Role of WDA(H) Holders in Combatting Falsified Medicines

A Wholesale Dealer’s Authorisation for Human Medicines [WDA(H)] is a license granted in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) to organisations that distribute human medicines. Holders of this license are required to meet stringent regulatory standards to ensure the safe and compliant distribution of medicines. Burlington Pharma, as a WDA(H) holder, plays a pivotal role in mitigating the risks of falsified medicines entering the supply chain. Here’s how:

1. Ensuring Supply Chain Integrity and Regulatory Compliance

As a WDA(H) holder, Burlington Pharma operates under national and international regulations, such as those established by the MHRA in the UK and the European Medicines Agency (EMA).

WDA(H) holders like Burlington Pharma are subject to rigorous regulatory scrutiny from regulatory agencies and are required to have robust Quality Management Systems in place to ensure that medicines are sourced from legitimate manufacturers and suppliers. This includes verifying that every product in the supply chain meets Good Distribution Practices (GDP), a European and UK standard designed to prevent falsified medicines from entering circulation.

Burlington Pharma conducts thorough due diligence on all suppliers and manufacturers, ensuring that:

• Suppliers are licensed and reputable.
• Medicines are authentic, with documented proof of origin.
• Proper storage and transportation protocols are followed to maintain the integrity of the medicine.

2. Batch Tracking and Traceability

One of the major advantages of working with a WDA(H) holder is the batch-level tracking of medicines. Burlington Pharma provides full traceability, allowing healthcare providers to know exactly where and when a product was sourced, and by whom. This traceability helps in:

• Quickly identifying and isolating any compromised batches in the event of recalls.
• Ensuring that medicines administered to patients are sourced from legitimate channels.
• Preventing counterfeit products from being mixed with authentic stock.

3. Auditing and Supplier Verification

Burlington Pharma frequently conducts supplier audits, ensuring that partners maintain the highest standards of quality control. This proactive approach to supplier risk management prevents falsified medicines from reaching healthcare providers. By working with audited suppliers, healthcare professionals can trust that the medicines they administer to patients have been sourced responsibly and are safe for use.

5. Training and Support

In addition to product procurement, Burlington Pharma provides training and support to healthcare professionals on the best practices for handling medicines, detecting potential falsifications, and ensuring compliance with regulatory requirements. This support enables healthcare providers to be vigilant in their practice, maintaining high standards of patient care and reducing the risk of counterfeit drugs affecting patient outcomes.

Conclusion

Falsified medicines pose a significant threat to both patient safety and the integrity of healthcare practices. For healthcare professionals, the consequences of administering these counterfeit products can be severe, leading to compromised patient outcomes, damage to professional reputation, and public health risks.

By working with a WDA(H) holder like Burlington Pharma, healthcare professionals can ensure that their medicine procurement processes are secure, reliable, and fully compliant with regulatory standards. With its commitment to supply chain integrity, traceability, and auditing, Burlington Pharma helps protect both patients and healthcare providers from the dangers of falsified medicines, allowing them to focus on delivering the best possible care.

1. Understanding Falsified Medicines

The European Medicines Agency (EMA) defines falsified medicines as those that misrepresent:

• Identity: Incorrect labelling, packaging, or brand.
• Source: False information regarding the manufacturer, country of origin, or marketing authorisation holder.
• Ingredients: Incorrect, insufficient, or inactive ingredients.

Unlike legitimate generics or parallel imports, falsified medicines compromise safety, efficacy, and quality, making their identification imperative for HCPs.

2. Key Indicators of Falsified Medicines

To effectively spot falsified medicines, HCPs should focus on the following aspects:

a) Packaging and Labelling

Falsified medicines often have minor errors or irregularities in packaging. Key things to check include:

• Spelling mistakes: Incorrect spelling on labels or instructions.
• Colour and print quality: Substandard or uneven printing, faded labels, or unusual colour schemes can indicate falsification.
• Tampered or broken seals: Missing or damaged security seals, or packages that appear to have been opened, should be treated with caution.
• Differences in batch numbers or expiry dates: Batch numbers or expiration dates on the outer packaging not matching the inner product.

b) Product Appearance

The physical appearance of the medicine itself can provide critical clues:

• Changes in colour, shape, or texture: If a product looks different from the original medication.
• Unexpected smell or taste: If patients report differences in the smell or taste of their medicine.
• Tablet or capsule inconsistencies: Variations in the size or weight of tablets and capsules within the same pack.

c) Medicine Efficacy and Patient Response

• Therapeutic failure: Patients experiencing diminished therapeutic effects or adverse reactions, despite following proper dosage, should prompt an investigation into the medicine’s authenticity.
• Unexplained side effects: If patients report unexpected side effects, this could be due to incorrect ingredients or unsafe impurities.

d) Price Discrepancies

Significantly lower prices compared to the standard market price for a specific medicine could indicate it is falsified. While legitimate price reductions exist, HCPs should be cautious of unusually discounted products.

3. Regulatory Frameworks and Safety Features

a) Falsified Medicines Directive (FMD)

The Falsified Medicines Directive (FMD) introduced by the EU, establishes requirements to combat falsified medicines in the legal supply chain. A key feature of the FMD is the Unique Identifier (UI), a 2D barcode placed on all prescription medicines, enabling verification of authenticity before dispensing. The UI includes:

• Product code
• Serial number
• Batch number
• Expiry date

HCPs can scan these barcodes to confirm the medicine’s legitimacy. Additionally, an anti-tampering device (ATD) should be present on the outer packaging of the product. Any tampering or absence of an ATD could signal a falsified product.

The ‘safety features’ elements of the EU FMD (FMD, 2011/62/EU) and Delegated Regulation (2016/161) ceased to have effect in Great Britain from 31 December 2020 due to Brexit.

This means that pharmacies (and other end users such as wholesalers, hospitals and others handling or supplying medicines, including dispensing doctors) will no longer be required by law to verify and decommission unique identifiers on prescription medicine packs.

b) MHRA Yellow Card Scheme

Healthcare professionals should utilise the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme [link https://yellowcard.mhra.gov.uk/] to report any suspicions of falsified medicines. This system allows healthcare providers to share concerns about medicines that appear counterfeit or substandard, contributing to nationwide surveillance and mitigation efforts.

4. Sources of Falsified Medicines

Healthcare professionals must remain vigilant about where medicines are sourced. In the UK, the legitimate supply chain, which includes licensed pharmacies, wholesale dealers, and hospitals, is closely regulated. However, falsified medicines can still infiltrate the system through:

• Unregulated online pharmacies: Purchasing from websites without valid UK licences increases the risk of counterfeit products. Legitimate online pharmacies will have the voluntary internet pharmacy logo displayed on their website to give reassurance to patients that they’re buying medicines online from a registered pharmacy that are up to the General Pharmaceutical Council’s (GPhC’s) standards.

• Unregulated online or physical sellers: Human medicines purchased directly from individuals, through social media or any unreputable website are likely not authorised to sell them.
• Suspicious suppliers: Any third-party suppliers offering medications at vastly reduced prices or without proper documentation should be scrutinised.

5. Educating Patients and Staff

Healthcare professionals play a crucial role in educating both colleagues and patients about the risks of falsified medicines. Ensure that:

• Patients are advised to only buy medicines from trusted, licensed sources.
• HCPs are trained to recognise suspicious packaging and products upon receipt, during dispensing and before administration of the product, and how to handle potential falsified medicines.
• Robust stock management processes are in place in the healthcare facility, especially when ordering and receiving stock.
• Your healthcare facility only purchase medicines from reputable WDA(H) holders. You can ascertain a supplier’s licence details on the MHRA-GMDP website

6. What to Do if You Suspect a Falsified Medicine

If you suspect that a medicine might be falsified, take immediate action:

• Quarantine the product: Isolate the suspected medicine and prevent it from reaching patients.
• Report to the MHRA: Use the Yellow Card Scheme  or the Medicines Enforcement contact to notify the MHRA of your suspicions, providing details such as batch numbers and packaging discrepancies.
• Notify your pharmacy lead or procurement team: They may need to trace the source of the medicine and liaise with suppliers.
• Counsel patients: If a patient has been dispensed a falsified medicine, provide them with appropriate advice, including monitoring for adverse effects or lack of efficacy.

7. Conclusion

For healthcare professionals in the UK, identifying falsified medicines is an essential aspect of ensuring patient safety and maintaining the integrity of medical treatments. By staying informed of regulatory guidelines, carefully inspecting medicines and packaging, and leveraging reporting tools like the MHRA Yellow Card Scheme, HCPs can play a pivotal role in detecting and preventing the distribution of falsified medicines.

Remaining vigilant in this regard is key to protecting patients and upholding the standards of healthcare delivery in the UK.